PCR detection of Leishmania in clinical material. Five microliters of the supernatant of boiled dermal scrapings or lesion aspirates (prepared as described in Materials and Methods) was amplified by the multiplex assay. Lane 1, water (negative control); lane 2, dermal scraping from a nonleishmanial cutaneous lesion (Nicaragua); lane 3, normal human buccal scraping (Nicaragua); lane 4, dermal scraping from an atypical cutaneous lesion from patient LC9853 (Leon, Nicaragua); lane 5, dermal scraping from an atypical cutaneous lesion from patient LC9786 (Apompua, Nicaragua); lane 6, lesion aspirate from a hamster infected with L. mexicana (Bolivia); lane 7, lesion aspirate from a hamster infected with L. mexicana (Bolivia); lane 8, dermal scraping from a cutaneous lesion from patient LC9708 (Nicaragua); lane 9, dermal scraping from a cutaneous lesion from patient LC11 (Nicaragua); lane 10, dermal scraping from a cutaneous lesion from patient LC9767 (Nicaragua); lane 11, dermal scraping from a cutaneous lesion from patient RG10 (Nicaragua); lane 12, dermal scraping from a cutaneous lesion from a patient from CPMC; lane M, 100-bp ladder (Gibco BRL; the lowest band shown is 100 bp); lane 13, L. chagasi DNA (MHOM/HN/87/029); lane 14, L. mexicana DNA (MNYC/BZ/62/M379); lane 15, L. braziliensis DNA (MHOM/BR/84/LTB300). L. don., L. donovani; L. mex., L. mexicana; L. braz., L. braziliensis.